In the United States Court of Federal Claims
                                    OFFICE OF SPECIAL MASTERS
                                          Filed: March 3, 2020

* * * * * * * *                     *    *    *   *    *
LANCE ANTOLICK and                                     *
ALYSON ANTOLICK,                                       *        UNPUBLISHED
on behalf of L.A.,                                     *
                                                       *        No. 16-1460V
                           Petitioners,                *
v.                                                     *        Special Master Gowen
                                                       *
SECRETARY OF HEALTH                                    *        Motion for Dismissal Decision; Diphtheria-
AND HUMAN SERVICES,                                    *        Tetanus-Acellular Pertussis (“DTaP”);
                                                       *        Inactivated Polio (“IPV”); Haemophilus
                           Respondent.                 *        Influenzae Type B (“Hib”); Boatmon.
*    * *     *    *    *   * * * *            *   *    *

Andrew D. Downing, Van Cott & Talamante, PLLC, Phoenix, AZ, for petitioners.
Robert P. Coleman, United States Department of Justice, Washington, DC, for respondent.

                                                    DECISION1

        On November 4, 2016, Lance Antolick and Alyson Antolick (“petitioners”), acting on
behalf of their minor child L.A., filed a petition in the National Vaccine Injury Compensation
Program.2 Petitioners alleged that L.A. suffered injuries as a result of the diphtheria-tetanus-
acellular pertussis (“DTaP”), inactivated polio virus (“IPV”), and haemophilus influenzae type B
(“Hib”) vaccine that he received on November 4, 2013. Petition (ECF No. 1), amended on
January 16, 2017 (ECF No. 15). The information in the record, does not establish entitlement to
compensation.


1
  Pursuant to the E-Government Act of 2002, see 44 U.S.C. § 3501 note (2012), because this opinion contains a
reasoned explanation for the action in this case, I am required to post it on the website of the United States Court of
Federal Claims. The court’s website is at http://www.uscfc.uscourts.gov/aggregator/sources/7. This means the
opinion will be available to anyone with access to the Internet. Before the opinion is posted on the court’s
website, each party has 14 days to file a motion requesting redaction “of any information furnished by that party:
(1) that is a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that
includes medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of
privacy.” Vaccine Rule 18(b). An objecting party must provide the court with a proposed redacted version of the
opinion.

party files a motion for redaction within 14 days, the opinion will be posted on the
court’s website without any changes.

National Vaccine Injury Compensation Program is set forth in Part 2 of the National Childhood Vaccine
Injury Act of 1986, Pub. L. No. 99-660, 100 Stat. 3755, codified as amended, 42 U.S.C. §§ 300aa-1 to -34 (2012)
(Vaccine Act or the Act). All citations in this decision to individual sections of the Vaccine Act are to 42 U.S.C.A. §
300aa.
        On March 3, 2020, petitioners filed a motion for a decision dismissing the petition in
light of the Federal Circuit’s decision in Boatmon v. Sec’y of Health & Human Servs., 

(Fed. Cir. 2019). Petitioners’ Motion (“Pet. Mot.”) (ECF No. 76). Boatmon involved
sudden unexplained infant death syndrome (SUIDS, also referred to as SIDS). In this case, L.A.
did not pass away. However, petitioners aver that there are similar issues at hand. Pet. Mot. at ¶
4. Petitioners aver that it would appear that the theory presented in Boatmon is no longer viable
in the Vaccine Program.

5. Under these circumstances, petitioners feel that to proceed
further would be unreasonable and would waste the resources of the Court and the Vaccine
Program.
 

6. Petitioners understand that a decision by the special master dismissing their
petition will result in a judgment against them and that such a judgment will end all of their
rights in the Vaccine Program.
 

7. Petitioners intend to protect their rights to file a civil
action in the future.
 

8.

         To receive compensation in the Vaccine Program, petitioners have the burden of proving
either: (1) that the vaccinee suffered a “Table Injury,” i.e., an injury beginning within a specified
period of time following receipt of a corresponding vaccine listed on the Vaccine Injury Table (a
“Table injury”) or (2) that the vaccinee suffered an injury that was caused-in-fact by a covered
vaccine. §§ 13(a)(1)(A); 11(c)(1). An examination of the record does not contain persuasive
evidence that L.A. suffered a “Table Injury.” Further, the record does not contain persuasive
evidence indicating that petitioner’s alleged injury was vaccine-caused or in any way vaccine-
related.

       Moreover, under the Vaccine Act, the Vaccine Program may not award compensation
based on the petitioner’s claims alone. Rather, the petitioner must support the claim with either
medical records or the opinion of a competent medical expert. § 13(a)(1). In this case, the
medical records are insufficient to establish entitlement and petitioners’ experts have not
presented opinion(s) that support a finding of entitlement in light of the Federal Circuit’s recent
decision in 
Boatmon, 941 F.3d at 1361-62
.

       Thus, petitioners’ motion is GRANTED. This matter is DISMISSED for insufficient
proof. The Clerk of the Court shall enter judgment accordingly.3

        IT IS SO ORDERED.
                                                                       s/Thomas L. Gowen
                                                                       Thomas L. Gowen
                                                                       Special Master




3
 Entry of judgment is expedited by each party’s filing notice renouncing the right to seek review. Vaccine Rule
11(a).


                                                         2